Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads

Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective

Ozempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.

The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against lower doses of Novo Nordisk’s medicines.